Japanese encephalitis virus structural and nonstructural proteins expressed in escherichia coli induce protective immunity in mice

Microbes and Infection

Volumn 14, Issue 2, 2012, Pages 169-176

  Tafuku, Senji ^a,b   Miyata, Takeshi ^a   Tadano, Masayuki ^a   Mitsumata, Ryotarou ^a,b,c   Kawakami, Hirochika ^a,b   Harakuni, Tetsuya ^a   Sewaki, Tomomitsu ^b   Arakawa, Takeshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b GenoLac BL Corporation   (Japan)

^c DENKA COMPANY LIMITED   (Japan)

Author keywords

Adjuvant; E protein; Japanese encephalitis virus; Mucosal vaccine; NS1; Recombinant proteins

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 2; JAPANESE ENCEPHALITIS VACCINE; JAPANESE ENCEPHALITIS VIRUS E PROTEIN; NONSTRUCTURAL PROTEIN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IN VITRO STUDY; JAPANESE ENCEPHALITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS NEUTRALIZATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; ESCHERICHIA COLI; FEMALE; IMMUNOGLOBULIN G; INTERLEUKIN-17; INTERLEUKIN-2; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; VACCINES, INACTIVATED; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

ESCHERICHIA COLI; JAPANESE ENCEPHALITIS VIRUS; MUS;

EID: 84856007755     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2011.09.004     Document Type: Article

References (36)

1. WHO, Vector-borne Viral Infections. http://www.who.int/vaccine_research/diseases/vector/en/print.html.
2. National Institute of Infectious Diseases J, National Epidemiological Surveillance of Vaccine-preventable Diseases. http://idsc.nih.go.jp/yosoku/JE/JEmap2009-E.html.
3. Wilder-Smith A., Freedman D.O. Japanese encephalitis: is there a need for a novel vaccine?. Expert Rev. Vaccines 2009, 8:969-972.
4. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines 2008, 7:689-693.
5. Beasley D.W., Lewthwaite P., Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin. Biol. Ther. 2008, 8:95-106.
6. Paulke-Korinek M., Kollaritsch H. Japanese encephalitis and vaccines: past and future prospects. Wien. Klin. Wochenschr. 2008, 120:15-19.
7. Bharati K., Vrati S. Japanese encephalitis: development of new candidate vaccines. Expert Rev. Anti Infect. Ther. 2006, 4:313-324.
8. Kaur R., Vrati S. Development of a recombinant vaccine against Japanese encephalitis. J. Neurovirol. 2003, 9:421-431.
9. Solomon T. Control of Japanese encephalitis - within our grasp?. N. Engl. J. Med. 2006, 355:869-871.
10. Jelinek T. Ixiaro: a new vaccine against Japanese encephalitis. Expert Rev. Vaccines 2009, 8:1501-1511.
11. Kollaritsch H., Paulke-Korinek M., Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 2009, 9:921-931.
12. Jones T. A chimeric live attenuated vaccine against Japanese encephalitis. Expert Rev. Vaccines 2004, 3:243-248.
13. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2003, 2:727-735.
14. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., Flach C.F., George-Chandy A., Harandi A.M., Lebens M., Lehner T., Lindblad M., Nygren E., Raghavan S., Sanchez J., Stanford M., Sun J.B., Svennerholm A.M., Tengvall S. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 2005, 97:181-188.
15. Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Kohama H., Tachibana M., Matsuzaki G., Torii M., Arakawa T. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect. Immun. 2010, 78:3773-3782.
16. Arakawa T. Adjuvants: no longer a 'dirty little secret', but essential key players in vaccines of the future. Expert Rev. Vaccines 2011, 10:1-5.
17. Fei-fei G., Jian W., Feng X., Li-ping S., Quan-yun S., Jin-ping Z., Pu-yan C., Pei-hong L. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine. Vaccine 2008, 26:5590-5594.
18. Harakuni T., Kohama H., Tadano M., Uechi G., Tsuji N., Matsumoto Y., Miyata T., Tsuboi T., Oku H., Arakawa T. Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus. Jpn. J. Infect. Dis. 2009, 62:37-45.
19. Rauthan M., Kaur R., Appaiahgari M.B., Vrati S. Oral immunization of mice with Japanese encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies. Microbes Infect. 2004, 6:1305-1311.
20. Verma S.K., Kumar S., Gupta N., Vedi S., Bhattacharya S.M., Lakshmana Rao P.V. Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice. Vaccine 2009, 27:6905-6909.
21. Alka Bharati K., Malik Y.P., Vrati S. Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med. Microbiol. Immunol. 2007, 196:227-231.
22. Wu H.H., Chen C.T., Lin Y.L., Lee S.T. Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming-protein boosting immunization strategies. Vaccine 2004, 22:793-800.
23. Wu S.C., Yu C.H., Lin C.W., Chu I.M. The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 2003, 21:2516-2522.
24. Chia S.C., Leung P.S., Liao C.P., Huang J.H., Lee S.T. Fragment of Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice from virus challenge. Microb. Pathog. 2001, 31:9-19.
25. Lin C.W., Liu K.T., Huang H.D., Chen W.J. Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus. Biotechnol. Lett. 2008, 30:205-214.
26. Mason P.W., McAda P.C., Dalrymple J.M., Fournier M.J., Mason T.L. Expression of Japanese encephalitis virus antigens in Escherichia coli. Virology 1987, 158:361-372.
27. Igarashi A. Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses. J. Gen. Virol. 1978, 40:531-544.
28. Okuno Y., Fukunaga T., Tadano M., Okamoto Y., Ohnishi T., Takagi M. Rapid focus reduction neutralization test of Japanese encephalitis virus in microtiter system. Brief report. Arch. Virol. 1985, 86:129-135.
29. Seif S.A., Morita K., Matsuo S., Hasebe F., Igarashi A. Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine 1995, 13:1515-1521.
30. Lin C.W., Wu S.C. A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J. Virol. 2003, 77:2600-2606.
31. Cecilia D., Gould E.A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 1991, 181:70-77.
32. Lee J.B., Jang J.E., Song M.K., Chang J. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS ONE 2009, 4:e5190.
33. Goncharova E., Ryzhikov E., Poryvaev V., Bulychev L., Karpyshev N., Maksyutov A., Ryzhikov A.B. Intranasal immunization with inactivated tick-borne encephalitis virus and the antigenic peptide 89-119 protects mice against intraperitoneal challenge. Int. J. Med. Microbiol. 2006, 296(Suppl. 40):195-201.
34. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
35. O'Connor R.A., Taams L.S., Anderton S.M. Translational mini-review series on Th17 cells: CD4 T helper cells: functional plasticity and differential sensitivity to regulatory T cell-mediated regulation. Clin. Exp. Immunol. 2010, 159:137-147.
36. Datta S.K., Sabet M., Nguyen K.P., Valdez P.A., Gonzalez-Navajas J.M., Islam S., Mihajlov I., Fierer J., Insel P.A., Webster N.J., Guiney D.G., Raz E. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10638-10643.